Teva settlement with QVAR end payors in US antitrust case gets preliminary nod
MLex Summary: Teva Pharmaceuticals’ $35 million settlement with end-payor plaintiffs has been granted preliminary approval by a US federal judge to resolve US claims accusing it of illegally delaying generic competition...To view the full article, register now.
Already a subscriber? Click here to view full article